Calithera Biosciences (CALA) Reports Q3 Loss of $0.49/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Calithera Biosciences Reports Third Quarter 2015 Financial Results and Recent Highlights
November 9, 2015 4:05 PM EST-Single Agent Solid Tumor Clinical Benefit Seen With Tumor Metabolism Inhibitor CB-839
-Continued Signs of Activity, Tolerability, and Durability
-First Preclinical Data Presented For Immuno-Oncology Arginase Inhibitor CB-1158
-IND filing Remains on Track for 1H 2016
-Calithera to Host Conference Call Today at 4:15pm Eastern Time
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage... More
